Cassava’s Alzheimer’s drug fails in late-stage study
By Thomson ReutersNov 25, 2024 | 6:37 AM
(Reuters) – Cassava Sciences on Monday said its experimental Alzheimer’s disease drug did not meet the main or secondary goals in a late-stage study.
(Reporting by Bhanvi Satija in Bengaluru; Editing by Tasim Zahid)
For the health and safety of everyone, our offices are temporarily closed to the public. If you have won a prize from us we will be mailing it to you or will contact you with specific information needed to redeem your prize. Feel free to call us with questions during weekday business hours at 715-842-1672.
